HeartBeam, Inc. (BEAT) Stock Score, Valuation & Financial Research

HeartBeam, Inc. is in the Healthcare sector and Medical - Specialties industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BEAT

HeartBeam, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.58. These figures are a research snapshot, not a buy or sell recommendation.

What HeartBeam, Inc. does

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

HeartBeam is a medical technology company that generates revenue through the commercialization of its HeartBeam System, a cable-free, ambulatory 12-lead ECG device. The company utilizes a business model focused on selling or leasing its proprietary hardware and software platform to concierge physicians, preventive cardiology groups, and hospital cardiology departments.

Products and services

  • The HeartBeam System, which includes a credit card-sized 3D ECG recording device, a patient application, a physician portal, and cloud-based 12-lead ECG synthesis software for arrhythmia assessment.

Brands and product families

  • HeartBeam System — The company's primary platform for cardiac signal recording and arrhythmia assessment. Source

Customer types

Concierge physicians; Preventive cardiology practices; Cardiology departments of hospitals.

Suppliers, materials and equipment

  • Unnamed contract manufacturers and component suppliers — The company relies on third-party manufacturers and suppliers for the production of its medical devices and components. Source

Business strengths to evaluate

  • FDA-cleared cable-free 12-lead ECG technology Source
  • Robust clinical data from the VALID-ECG pivotal study Source

Business risks and research considerations

  • History of operating losses and potential need for additional capital Source
  • Dependence on successful commercialization of the HeartBeam System Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BEAT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.58
Market capitalization:
32.42M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -20.3M
Free cash flow:
USD -14.59M
Cash:
USD 8.72M
Total debt:
USD 0.00
EPS:
USD -0.52

What stands out

  • Free cash flow is USD -14.59M, negative for the stored period.
  • The balance sheet shows USD 8.72M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 8.72M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BEAT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BEAT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BEAT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BEAT to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of BEAT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research BEAT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.